Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Merus N.V. CS (MRUS)

Merus N.V. CS (MRUS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,336,369
  • Shares Outstanding, K 58,688
  • Annual Sales, $ 43,950 K
  • Annual Income, $ -154,940 K
  • 60-Month Beta 1.10
  • Price/Sales 54.04
  • Price/Cash Flow N/A
  • Price/Book 6.56
Trade MRUS with:

Options Overview Details

View History
  • Implied Volatility 107.97% ( -5.65%)
  • Historical Volatility 29.15%
  • IV Percentile 90%
  • IV Rank 76.36%
  • IV High 131.45% on 02/22/24
  • IV Low 32.12% on 08/14/23
  • Put/Call Vol Ratio 1.46
  • Today's Volume 59
  • Volume Avg (30-Day) 365
  • Put/Call OI Ratio 2.55
  • Today's Open Interest 7,099
  • Open Int (30-Day) 7,906

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.83
  • Number of Estimates 8
  • High Estimate -0.61
  • Low Estimate -1.09
  • Prior Year -0.86
  • Growth Rate Est. (year over year) +3.49%

Price Performance

See More
Period Period Low Period High Performance
1-Month
39.27 +3.00%
on 04/19/24
46.49 -13.00%
on 03/25/24
-5.48 (-11.93%)
since 03/22/24
3-Month
33.60 +20.39%
on 01/25/24
52.03 -22.26%
on 03/01/24
+5.57 (+15.97%)
since 01/22/24
52-Week
18.21 +122.13%
on 05/02/23
52.03 -22.26%
on 03/01/24
+18.45 (+83.86%)
since 04/21/23

Most Recent Stories

More News
New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:PYXS),(NASDAQ:AZN),(NYSE:LLY),(NASDAQ:MRUS) EQNX::TICKER_END

ONCY : 1.0400 (-1.89%)
ONC.TO : 1.46 (+1.39%)
PYXS : 4.53 (+8.89%)
AZN : 70.13 (+2.30%)
LLY : 731.33 (+0.69%)
MRUS : 40.45 (+1.61%)
New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review

/PRNewswire/ -- USA News Group - Since September 2022, the US Food and Drug Administration (FDA) has seen new treatments for pancreatic cancer that are worthy...

ONC.TO : 1.46 (+1.39%)
ONCY : 1.0400 (-1.89%)
PYXS : 4.53 (+8.89%)
AZN : 70.13 (+2.30%)
LLY : 731.33 (+0.69%)
MRUS : 40.45 (+1.61%)
Breakthroughs in Pancreatic Cancer Treatment: How FDA Designations are Changing the Game

USA News Group – Since September 2022, the US Food and Drug Administration (FDA) has seen new treatments for pancreatic cancer that are worthy of further investigation or approval. Known as one of the...

ONCY : 1.0400 (-1.89%)
ONC.TO : 1.46 (+1.39%)
PYXS : 4.53 (+8.89%)
AZN : 70.13 (+2.30%)
LLY : 731.33 (+0.69%)
MRUS : 40.45 (+1.61%)
Pancreatic Cancer Research Gains Momentum Amidst Soaring Young-Onset Cases

/PRNewswire/ -- USA News Group - The seriousness of pancreatic cancer continues to grow, with increasing alarm since The Lancet published an analysis back in...

ONC.TO : 1.46 (+1.39%)
ONCY : 1.0400 (-1.89%)
MRUS : 40.45 (+1.61%)
GH : 17.59 (+9.46%)
MDT : 80.57 (+1.37%)
NVDA : 795.18 (+4.35%)
Pancreatic Cancer Research Gains Momentum Amidst Soaring Young-Onset Cases

FN Media Group Presents USA News Group News Commentary   Vancouver, BC – September 26, 2023 – USA News Group  –  The seriousness of pancreatic cancer continues to grow, with increasing alarm since...

ONCY : 1.0400 (-1.89%)
ONC.TO : 1.46 (+1.39%)
MRUS : 40.45 (+1.61%)
GH : 17.59 (+9.46%)
MDT : 80.57 (+1.37%)
NVDA : 795.18 (+4.35%)
Pancreatic Cancer's Alarming Surge in Young Adults Sparks Research into New Treatments

USA News Group – The seriousness of pancreatic cancer continues to grow, with increasing alarm since The Lancet published an analysis back in April 2023, showing a rising incidence of pancreatic cancer...

ONCY : 1.0400 (-1.89%)
ONC.TO : 1.46 (+1.39%)
MRUS : 40.45 (+1.61%)
GH : 17.59 (+9.46%)
MDT : 80.57 (+1.37%)
NVDA : 795.18 (+4.35%)
Wall Street Analysts Believe Merus N.V. (MRUS) Could Rally 114.58%: Here's is How to Trade

The consensus price target hints at an 114.6% upside potential for Merus N.V. (MRUS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate...

MRUS : 40.45 (+1.61%)
Merus N.V. (MRUS) Reports Q1 Loss, Tops Revenue Estimates

Merus N.V. (MRUS) delivered earnings and revenue surprises of 19.63% and 27.76%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

MRUS : 40.45 (+1.61%)
CDTX : 0.5139 (-24.54%)
Aligos Therapeutics, Inc. (ALGS) Reports Q1 Loss, Lags Revenue Estimates

Aligos Therapeutics, Inc. (ALGS) delivered earnings and revenue surprises of -8.16% and 36.67%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...

ALGS : 0.8010 (+6.80%)
MRUS : 40.45 (+1.61%)
Analysts Estimate Merus N.V. (MRUS) to Report a Decline in Earnings: What to Look Out for

Merus N.V. (MRUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MRUS : 40.45 (+1.61%)
TSVT : 4.65 (+2.88%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Merus B.V. is a clinical-stage immuno-oncology company developing bispecific antibody therapeutics, referred to as Biclonics. The company's bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial as a potential treatment for HER2-expressing solid tumors; MCLA-117, is...

See More

Key Turning Points

3rd Resistance Point 42.89
2nd Resistance Point 42.20
1st Resistance Point 41.32
Last Price 40.45
1st Support Level 39.75
2nd Support Level 39.06
3rd Support Level 38.18

See More

52-Week High 52.03
Last Price 40.45
Fibonacci 61.8% 39.11
Fibonacci 50% 35.12
Fibonacci 38.2% 31.13
52-Week Low 18.21

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar